Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for ...

Clinical studies in kidney transplantation have demonstrated that tegoprubart has the potential to improve graft survival and function while reducing the side effects associated with calcineurin ...

Restoring the gut microbiota through fecal microbiota transplantation reversed these effects. The treatment replenished CX3CR1-positive NK cells, reduced lung damage, and improved survival. Targeted ...

For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--#addf--MindImmune today announced a transformative $5 million award from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate development of its lead ...

Cassava Sciences (SAVA) said it will change its name to Filana Therapeutics, reflecting its focus on developing drugs that target the filamin A protein to treat central nervous system disorders. The ...

FAYETTEVILLE, GA, UNITED STATES, March 10, 2026 /EINPresswire.com/ -- Spinal cord injury often triggers a cascade of ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Please provide your email address to receive an email when new articles are posted on . Petrelintide is a once-weekly amylin analog currently under investigation for the treatment of obesity. The ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading ...